Canada’s medical cannabis landscape is facing a profound transformation.

Since the legalization of recreational marijuana in 2018, there has been a steep decline in both patient registrations and spending. The challenge now lies in deciphering the reasons and navigating future implications.

In a recent report by Zuanic & Associates, Canada's cannabis market shows growth but lags behind the U.S. in per capita spending and market share. Meet Pablo Zuanic who will further discuss these and many more findings at the Benzinga Cannabis Capital Conference in Chicago. Save the date: September 27 and 28.

Related Content: Canada's Cannabis Market Shows Steady Growth But Lags Behind US Counterparts

Numbers Don't Lie

Recent data from Health Canada and Statistics Canada underlined this downturn. As of March, only 212,700 patients were actively registered with federal licensees, down 38% from October 2018’s 345,520.

Financial patterns echo this change, with medical cannabis expenses for the …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.